What this test measures
Immunoglobulins are made up of heavy chains and light chains. The light chains come in two types: kappa (κ) and lambda (λ). Plasma cells normally make a small excess of light chains, which appear in serum as "free" light chains (FLC) — unbound to heavy chains. The serum free kappa light chain test quantifies these free κ chains; the test is reported together with free lambda and the κ/λ ratio.
In plasma cell disorders, malignant plasma cells produce a monoclonal excess of one light chain — either kappa or lambda. The κ/λ ratio becomes abnormal even when total light-chain levels remain near normal, so serum free light chains are very sensitive for detecting and monitoring myeloma and related disorders.
Why it matters
Serum free light chains are central to the diagnosis, prognosis, and monitoring of multiple myeloma, light-chain (Bence Jones) myeloma, AL amyloidosis, MGUS, and Waldenström macroglobulinaemia. The κ/λ ratio is a more sensitive marker than serum protein electrophoresis alone — modern criteria (IMWG) define light-chain myeloma using free light chain levels and ratio.
In India, where myeloma incidence is rising in older adults and where many patients present late, serum free light chain testing has improved early diagnosis and monitoring on treatment. A normalising κ/λ ratio is a marker of response; a rising abnormal ratio signals relapse before SPEP detects an M-spike. Free light chains are also affected by kidney function — they are normally cleared by kidneys, so both κ and λ rise in kidney failure but the ratio is preserved unless a plasma cell disorder coexists.
How to prepare
No fasting required. Continue all medications. Disclose any history of myeloma, MGUS, amyloidosis, or kidney disease. Most labs report kappa and lambda together so the ratio can be calculated — if only kappa is ordered, the interpretation is limited without lambda.
Markers & reference ranges
Reference ranges below are typical adult values. Your lab's reported range may differ slightly based on the assay platform and patient demographics — always read your report against the range printed on it.
| Marker | Normal range | If low | If high |
|---|---|---|---|
| Free Kappa Light Chain (Serum) (mg/L)[1][2][3] | 3.3 – 19.4 mg/L (with κ/λ ratio 0.26 – 1.65; renal range up to 3.1) | < 3.3 mg/L: uncommon in isolation. May indicate severely impaired humoral immunity or rarely a lambda-dominant plasma cell disorder (with low κ and high λ). | > 19.4 mg/L with abnormal κ/λ ratio (> 1.65): kappa-producing plasma cell disorder — multiple myeloma, MGUS, kappa light-chain myeloma, AL amyloidosis. > 19.4 mg/L with normal κ/λ ratio (0.26–1.65): polyclonal rise — kidney impairment, chronic infection, autoimmune disease. |
Free light chain interpretation
| κ/λ ratio | Interpretation |
|---|---|
| 0.26 – 1.65 | Normal balance (polyclonal) |
| > 1.65 | Kappa monoclonal excess — possible myeloma, MGUS, AL amyloid |
| < 0.26 | Lambda monoclonal excess — possible lambda myeloma, AL amyloid |
| Renal failure with preserved ratio | Polyclonal accumulation; kappa and lambda both rise but ratio normal (up to 3.1) |
Frequently asked questions
Why is the κ/λ ratio so important?
Plasma cell cancers produce a monoclonal excess of one light chain. Even when total kappa or lambda looks normal, the ratio shifts because one is going up while the other is suppressed. The ratio is therefore much more sensitive than either chain alone.
Can kidney disease change the result?
Yes. Kidney clearance of light chains is reduced in renal impairment, so both kappa and lambda rise. The ratio is usually preserved (extended renal reference range 0.37–3.1). An abnormal ratio outside the renal range still suggests a plasma cell disorder.
How is free light chain different from urine Bence Jones protein?
Urine Bence Jones protein detects light chains excreted in urine by older methods. Serum free light chain testing is much more sensitive — it picks up plasma cell disorders that urine testing misses. Modern myeloma diagnostic criteria emphasise serum FLC; urine testing remains useful for tracking 24-hour light chain excretion.
Should everyone over 60 be screened?
Routine population screening is not recommended. Test if there are clinical features suggesting myeloma — unexplained anemia, kidney failure, bone pain, hypercalcaemia, recurrent infections, or an M-protein on SPEP.
How is the test used after diagnosis?
Free light chains are used to monitor response — a falling κ/λ ratio (toward normal) supports response; a rising abnormal ratio suggests relapse. Free light chains often shift earlier than SPEP M-protein, giving an earlier warning.
What is AL amyloidosis?
A disease where misfolded light chains (usually lambda) deposit as amyloid fibrils in organs — heart, kidney, nerves, gut. Diagnosis requires biopsy with Congo-red staining and typing of the amyloid. Serum free light chains support diagnosis and monitoring.
Does this test fast?
No fasting needed.
Related Immunology tests
Tests commonly ordered alongside KAPPA LIGHT CHAIN, or that help interpret an unexpected result.
Sources & references
- NCBI StatPearls — Multiple Myeloma · accessed 2026-05-30T00:00:00.000Z
- NIH MedlinePlus — Free Light Chain Test · accessed 2026-05-30T00:00:00.000Z
- Mayo Clinic Labs — Kappa and Lambda Free Light Chains · accessed 2026-05-30T00:00:00.000Z
- IMWG — Multiple Myeloma Diagnostic Criteria · accessed 2026-05-30T00:00:00.000Z
Book with Zelnoo
Get your KAPPA LIGHT CHAIN test done at home — transparent prices, NABL-accredited labs.
Zelnoo lets you compare diagnostic test prices across NABL-accredited labs in Mumbai & Thane, book a free home phlebotomist visit, and receive digital reports in 24–48 hours into a consent-first report vault. No subscriptions, no membership fees — pay only for the test you book.
Book KAPPA LIGHT CHAIN now